Ligand id: 7499

Name: pembrolizumab

1. Carven GJ, Van Eenennaam H, Dulos GJ. (2010)
Antibodies to human programmed death receptor PD-1.
Patent number: US20100266617. Assignee: Organon NV. Priority date: 13/06/2008. Publication date: 21/10/2010.
2. FDA. 
FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL.
Accessed on 18/06/2018. Modified on 18/06/2018.,
3. Greaves P, Gribben JG. (2013)
The role of B7 family molecules in hematologic malignancy.
Blood, 121 (5): 734-44. [PMID:23223433]
4. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N. Engl. J. Med., 369 (2): 134-44. [PMID:23724846]
5. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012)
T cell coinhibition and immunotherapy in human breast cancer.
Discov Med, 14 (77): 229-36. [PMID:23114578]
6. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP et al.. (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N. Engl. J. Med., 374 (26): 2542-52. [PMID:27093365]
7. Tang PA, Heng DY. (2013)
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.
Curr Oncol Rep, 15 (2): 98-104. [PMID:23263823]